SOUTHBOROUGH, Mass. — Veristat announced plans to acquire Certara’s Regulatory and Medical Writing business, a move aimed at expanding its capabilities in supporting drug development and regulatory submissions.
The acquisition will add more than 200 industry experts to Veristat, strengthening its ability to assist clinical trial sponsors in navigating complex regulatory processes and bringing new therapies to market.
The deal is backed by WindRose Health Investors, a New York-based private equity firm that continues to support Veristat’s growth strategy.
Company officials said the addition of Certara’s team, known for its advisory services and expertise in clinical and non-clinical documentation, will enhance Veristat’s offerings across the drug development lifecycle, from early-stage research through regulatory submission.
“Over the past 30+ years, Veristat has strategically invested in organizations, people, and resources to help our clients solve their most complex clinical development, regulatory, and commercialization challenges,” said Kim Boericke, Chief Executive Officer of Veristat. “By combining our complementary strengths and talented teams, Veristat will have unmatched capabilities in biostats, medical writing, and regulatory affairs, made even stronger by a shared focus on science-based insights, strong client partnerships, innovation, and impact. We will be able to bring even more life-changing medical therapies to patients with unmet needs—and that’s an exciting prospect for all of us.”
The transaction is expected to close in the second quarter of 2026, subject to customary conditions. Until the deal is finalized, both companies will continue operating independently and serving their clients as usual.
